Summary
Stryker Corporation's 2008 10-K filing reveals a robust year of growth, with net sales reaching $6.7 billion, a 12% increase over 2007. This growth was driven by strong performance across both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing a notable 13% increase. Despite a challenging economic climate, particularly impacting hospital capital budgets in the latter half of the year, Stryker demonstrated resilience, with significant sales increases in key areas like knee implants (14%), trauma implants (18%), and patient handling equipment (18%). The company also reported a 16% increase in net earnings from continuing operations to $1.15 billion. Management highlighted its focus on innovation and new product introductions, such as the Tritanium Primary Hip System and the S3 Med/Surg Hospital Bed, as critical to its growth strategy. While the company faced some regulatory challenges, including warning letters related to quality systems, it actively cooperated with authorities to address these issues. Stryker also continued its share repurchase program, underscoring its commitment to returning value to shareholders.
Financial Highlights
52 data points| Revenue | $6.72B |
| Cost of Revenue | $2.13B |
| Gross Profit | $4.59B |
| R&D Expenses | $367.80M |
| SG&A Expenses | $2.63B |
| Operating Expenses | $3.07B |
| Operating Income | $1.52B |
| Interest Expense | $12.70M |
| Net Income | $1.15B |
| EPS (Basic) | $2.81 |
| EPS (Diluted) | $2.78 |
| Shares Outstanding (Basic) | 408.10M |
| Shares Outstanding (Diluted) | 413.60M |
Key Highlights
- 1Achieved 12% net sales growth, reaching $6.7 billion in 2008, driven by strong performance in both Orthopaedic Implants and MedSurg Equipment segments.
- 2Reported a 16% increase in net earnings from continuing operations to $1.15 billion, with diluted EPS of $2.78.
- 3Demonstrated significant international sales growth of 13%, contributing to overall revenue expansion.
- 4Experienced robust growth in key product categories, including knee implants (14%), trauma implants (18%), and patient handling equipment (18%).
- 5Continued investment in research and development, totaling $367.8 million, with a focus on new product introductions to drive future growth.
- 6Maintained a strong financial position with $701.1 million in cash and cash equivalents and substantial operating cash flow ($1.18 billion).
- 7Successfully navigated the challenging economic environment and addressed regulatory compliance issues, demonstrating operational resilience.